Acne 

Actinic Keratosis 

Aesthetics

Alopecia

Biologic Treatments for Moderate to Severe Atopic Dermatitis 

Atopic Dermatitis 

Buy-and-Bill

COVID-19

Case-Based Roundtable

Chronic Hand Eczema

Chronic Spontaneous Urticaria 

Drug Watch

Eczema

General Dermatology 

Hidradenitis Suppurativa

Melasma

NP and PA

Pediatric Dermatology

Pigmentary Disorders 

Practice Management 

Precision Medicine and Biologics

Prurigo Nodularis

Emerging Therapies Plaque Psoriasis

Treatments for Plaque Psoriasis 

Psoriasis 

Psoriatic Arthritis 

Rare Disease

Rosacea 

Skin Cancer (Nonmelanoma)

Skin Cancer

Vitiligo

Wound Care

News

Media

Around the Practice

Between The Lines

Case-Based Peer Perspective

Clinical Case Collective

DermView

Expert Perspectives

Fellows Face Off

Frontline Forum

Medical World News

Patient Perspectives

Podcasts

Readout360

Recognize and Refer

Conferences

Conference Coverage

Conference Listing

Events

Publication

Dermatology Times

CME/CE

Resources

DermIQ

Interactive Tools

Job Board

Partner Perspectives

Perspectives in Dermatology

Polls

Spot Test

Editorial Advisory Board

Partners

Subscribe

Articles

Jamie Restivo, MPAS, PA-C, shares her key takeaways from the second day of the recent Fall Clinical PA/NP Conference in Orlando, Florida.

Clinical Pearls from the 2025 Fall Clinical PA/NP Meeting: Day 2 

and joined the MJH Life Sciences team in February 2023. She attended Kent State University and earned a Bachelor of Science degree in journalism with minors in public relations and creative writing. She enjoys making and listening to music, reading, and spending time with her cats, Astrid and Marceline.

Videos

At SCALE 2025, Christina Feser, DO, FAAD, FAOCD, spotlighted the rapidly expanding pipeline of diverse therapies for patients with HS.

Christina Feser, DO, Shares Therapeutic Advances in Hidradenitis Suppurativa From SCALE 2025

Marie Bosslett is the assistant editor of 

 and joined the MJH Life Sciences team in October 2024. She attended Loyola University Maryland in Baltimore and earned a Bachelor of Arts in Communication with minors in marketing and writing. When she’s not writing, Marie enjoys going to concerts, reading on the beach, and spending time with friends and family.

Mercedes Gonzalez, MD, discusses the promising INTEGUMENT-INFANT trial, exploring a new non-steroidal treatment for infants with atopic dermatitis.

Investigating Roflumilast 0.05% Cream for Infant AD with Mercedes E. Gonzalez, MD

As the chair of the department of dermatology at the Icahn School of Medicine at Mount Sinai in New York City, Emma Guttman-Yassky, MD, PhD, and her team see roughly two thirds of dermatology patients in the city of New York and has become 1 of the 3 largest departments in the United States.

Discover promising advancements in vitiligo treatments, including innovative therapies and combination approaches that enhance skin repigmentation and improve patient quality of life.

Oral Ritlecitinib Plus nbUV-B Accelerates Repigmentation in Nonsegmental Vitiligo

Dermatology Times connects dermatology professionals with key skin disorder coverage, therapeutic strategies, clinical trial updates, and expert insights.

About

Advertise

Contact Us

Do Not Sell My Information

Terms and Conditions

Privacy Policy

Dermatology Times - Dermatology News and Clinical Insights

Facebook

Linkedin

Topics

Acne

Pigmentary Disorders

Practice Management

Psoriasis

Psoriatic Arthritis

Rosacea

1rem

Authors

More than $600,000 have been donated to raise awareness of melanoma with the #Stickit2Melanoma pledge.

Campaign Seeks to Increase Number of Individuals Visiting Dermatologists for Skin Check

Final Thoughts: The Importance of Comparative Studies in AD

Panelists offer concluding insights and emphasize the critical role of comparative studies in advancing atopic dermatitis treatment strategies.

clinical

Video Series

Renata Block, MMS, PA-C, speaks with melanoma survivor and patient advocate Brittany Groover.

Derm Dispatch: Melanoma Doesn't Wait -- Neither Should You

, Renata Block, PA-C, spoke with Brittanny Groover, a melanoma survivor and passionate advocate for skin cancer awareness. Groover, now in her late twenties, shared the deeply personal story of how she developed melanoma after years of frequent tanning, a habit formed in her teen years and encouraged by her environment. Growing up with her mother—who also loved tanning—Groover spent countless hours in the sun and later, in tanning beds. Even after beginning regular skin checks as a young adult, her belief that "it won’t happen to me" persisted until the moment it did.

Her diagnosis came after she noticed a mole on her shin growing in size and changing in appearance. Although she had an established history of annual dermatology visits, the COVID-19 pandemic disrupted her routine, delaying her next skin check. When she finally returned to the clinic, her dermatologist immediately identified the mole as melanoma—later confirmed by biopsy. She underwent a wide local excision with a skin graft, followed by a sentinel lymph node biopsy that revealed the cancer had begun to spread. Brittany then endured a year of immunotherapy (Keytruda), which led to intense adverse effects such as colitis and pancreatitis—complications she now says were worse than the cancer itself.

Now cancer-free, Groover has become a powerful voice for melanoma awareness, particularly among younger audiences. She shares her journey unfiltered on social media to combat the perception that skin cancer is minor or merely cosmetic. Her goal is to show that melanoma is not “just skin cancer” and can have life-altering consequences. She encourages clinicians to engage young patients through real-life stories and hands-on education, rather than brochures alone. Teaching teens how to perform skin checks, understand sun protection, and recognize warning signs could make all the difference.

Through her work with initiatives like “Don’t Fry Day” and the National Council on Skin Cancer Prevention, Groover is helping reshape how young people understand skin health. Her message is clear: melanoma doesn’t discriminate by age, and prevention must start early.

Renata Block, PA-C, speaks with patient advocate Brittanny Groover on her experience, how to educate young patients, and understanding the psychosocial impact of melanoma.

Derm Dispatch: Melanoma Doesn’t Wait—Neither Should You

POLL: Women are More Likely to Develop Hidradenitis Suppurativa - True or False? 

“We had a great session with a wonderful patient advocate who was gracious enough to share her story with us of living with atopic dermatitis most of her life. From her story and from everything she shared, we're able to see how this disease is a multi-dimensional, multi-factorial, heterogeneous disease that can take on different forms depending on what stage a patient is in life. It was a reminder for us to really listen to our patients,” said Maureen Offiah, MD, in an interview with 

Offiah, a board-certified dermatologist at Hattiesburg Clinic in Mississippi, attended the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee, and shared key highlights on atopic dermatitis (AD) that she will take back to her practice and patients.

Maureen Offiah, MD, reflected on the key takeaways as an attendee at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee.

A Clinician’s Perspective of RAD 2025: Part 1

Early sessions at RAD focused on the psychosocial impacts of AD, detailing how chronic itch, often compared to a pain syndrome, can significantly impair patient quality of life. Mental health effects, such as anxiety, depression, and family-wide impact, were discussed in detail. Offiah noted that discussions focused on the need to individualize treatment by addressing not just skin clearance but also the burden of symptoms such as itch and sleep disturbance.

A particularly impactful segment to Offiah included a patient advocate’s testimony, which provided clinicians with insight into the lived experience of AD. The overall message was that clinicians should actively listen to patients and resist the tendency to standardize care across presentations. Offiah emphasized that seemingly minor body surface area involvement can hide the true severity of the disease, particularly when symptoms disproportionately affect quality of life.

The sessions also introduced emerging considerations such as alopecia in AD. Offiah highlighted a discussion on scalp pruritus and burning, which expanded the diagnostic framework to include AD-associated alopecia alongside more commonly considered conditions such as allergic contact dermatitis, seborrheic dermatitis, and psoriasis. The session emphasized the importance of maintaining a broad differential when evaluating hair loss or scalp symptoms in patients with AD.

Treatment-focused panels provided an in-depth comparison of the currently FDA-approved systemic and topical therapies, including biologics and JAK inhibitors. Offiah expressed her appreciation for the way these therapies were analyzed in detail, particularly around the mechanisms of action, patient selection, and long-term safety. As Offiah noted, the abundance of therapeutic options now available, although effective, also requires careful consideration. The RAD sessions helped clarify optimal strategies for aligning specific agents with individual patient needs.

Shahriari M. The psychosocial burden of AD. Presented at: 2025 Revolutionizing Atopic Dermatitis Conference; June 6-7, 2025; Nashville, TN.

Mayo T. Complex cases: AD & hair loss. Presented at: 2025 Revolutionizing Atopic Dermatitis Conference; June 6-7, 2025; Nashville, TN.

The 2025 Revolutionizing Atopic Dermatitis (RAD) Conference highlighted the multifaceted nature of atopic dermatitis (AD), emphasizing the importance of individualized treatment approaches. Sessions addressed the psychosocial impacts of AD, including mental health effects and the need to consider symptoms like itch and sleep disturbance. Emerging topics such as AD-associated alopecia were discussed, expanding diagnostic frameworks. Treatment panels compared systemic and topical therapies, focusing on mechanisms, patient selection, and safety. The conference underscored the necessity of listening to patients and tailoring care to their unique experiences and needs.

To stay up-to-date with the latest dermatology news, sign up to receive our 

At-Home Facial Massage Methods Clinically Proven to Improve Skin Elasticity, Tone, and Contour

A new comparative study evaluated positive outcomes from patient use of a gua sha versus a facial roller over 8 weeks of treatment.

The Broader Spectrum of Sun Damage and Skin Protection

Visible and infrared light can worsen hyperpigmentation—especially in darker skin tones—so sunscreen must go beyond UV, says Susan Taylor, MD, FAAD.

Adam Friedman, MD, FAAD: Healing Spaces and Holistic HS Care

Adam Friedman, MD, FAAD, discusses the growing need for psychosocial support in hidradenitis suppurativa care and HS Connect’s role in closing the gap.

Looking Ahead to Povorcitininb for HS and the Availability of Generic Tofacitinib

At RAD 2025, Matthew Zirwas, MD, outlined 2 upcoming shifts in dermatology: the emergence of povorcitinib for hidradenitis suppurativa and the anticipated generic availability of tofacitinib.



A recent study compared the effects of gua sha and facial rollers on skin elasticity, tone, and contour over an 8-week period, showing positive outcomes. Additionally, the importance of comprehensive sun protection, including visible and infrared light, is emphasized, particularly for individuals with darker skin tones. Dr. Susan Taylor highlights the need for sunscreens that extend beyond UV protection. Dr. Adam Friedman discusses the importance of psychosocial support in hidradenitis suppurativa care, highlighting HS Connect's role in addressing this need.

Catch up on dermatology news, highlights, and insights from the past 24 hours.

Daily Derm Times: June 13, 2025

Dr. Gregory House, from the hit television show, “House,” became famous for uttering the catchphrase, “It’s not Lupus!” This was in the context of him dismissing Lupus as a diagnosis to whichever medical mystery that was bestowed upon him and his fictional all-star team of specialist physicians.

Hershel Dobkin, MD, FAAD, despite being a former semi-okay-amateur-stand-up-comedian prior to being a dermatologist, sadly does not possess a mystery medicine television show. What he does possess is the experience of sometimes telling men that their genital skin area concern is not genital warts, also known as Condyloma Acuminatum, to those who enjoy proper medical terminology. And yes, of course both men and women can get genital warts, but in honor of men’s health month this commentary will focus on male patients, and the taboo around addressing their skin in sensitive areas.

Much of what a dermatologist does is reassure. There are numerous benign and lesser known cutaneous growths and anatomical variation that have designated diagnostic terms that can resemble Harry Potter spells, but nonetheless pose no medical threat to the patient. Polythelia -- the term for accessory nipple, Poikiloderma of Civatte -- skin changes on the neck due to longterm sun exposure, and Idiopathic Guttate Melanosis -- light spots on extremities from aging and longterm sun exposure, are all examples of diagnoses the non-dermatologist, when heard, may perceive as diseases, but are simply no immediate cause for concern.

Moving south or “inferior” in anatomical terms, we enter a differential diagnosis often clouded by emotions and embarrassment. In contrast to the “innocent until proven guilty” legal principle in our country’s justice system, genital concerns are “warts until proven not warts” to the vast majority of patients. Fleshy bump on genitals? Warts! Red bump on genitals? Warts! Occasional itch while staring down old men in the sauna? Warts! These are very real and common chief complaints men have presented with while concerned for genital warts.

It takes a great deal of vulnerability, courage, and overcoming of fear for many men to even mention a genital area skin issue, and as shocking as it may seem to the layperson, it’s a dermatologist’s job to treat this like any other skin complaint so as to prevent a “judgy” or awkward situation.

I am therefore granted the honor of reassuring many male patients, “It’s not genital warts.” Ironically, this reassurance that a patient’s perceived sexually transmitted infection is nothing but a benign growth or comparably harmless diagnosis creates a sense of emotional relief second only to telling a patient a lesion is not skin cancer. Nonetheless, that is what I and all dermatologists are here for.

There are more than a few notorious genital warts imposers that routinely cause unnecessary anxiety in men who come into our clinics. To expand on the “It’s not genital warts” differential, here are a few of the top offenders: To begin, we start with Pearly Penile Papules. These white papules straddling the penile corona are nothing but a type of angiofibroma-a benign growth of blood vessels and fibrous tissue. While we’re in the neighborhood, let’s discuss Tyson’s glands, yellow papules on the penis comprised of ectopic sebaceous (oil) glands. More subtlety different, the widely known diagnosis of acrochordons (skin tags) commonly masquerade as genital warts to the unseasoned condyloma eye (dermatologists). Lastly, and not as fleshy as the others, is the notorious Angiokeratoma of Fordyce-red or purple vascular red or purple papules often on the scrotum.

Once the emphatic relief from receiving a reassuring diagnosis passes on my male patient’s minds, there are a select few who ask the million-dollar question, “how do you know it’s not genital warts?” As with most other dermatological diagnoses, a dermatologist’s training and clinical experience is rooted in endless hours studying common and obscure dermatoses and pattern recognition in clinic settings across various skin types. The short answer to the above patient’s question would be, “Because I am a dermatologist,” but this might come across a tad bit pretentious. One day I may have enough dermatology “street cred” to answer this question with, “It’s not warts” while leaving the exam room like an 80s action hero walking away in slow motion from an explosion. The moral of this story is that a certain sensitive anatomical location shouldn’t hinder a concerned male patient from getting evaluated by a dermatologist -- it is all skin to us.

Dr. Hershel Dobkin, a dermatologist, emphasizes the importance of addressing male genital skin concerns without embarrassment, particularly during men's health month. Many benign conditions, such as Pearly Penile Papules and Tyson's glands, are often mistaken for genital warts, causing unnecessary anxiety. Dermatologists play a crucial role in reassuring patients by distinguishing these benign conditions from sexually transmitted infections. Their expertise is rooted in extensive training and pattern recognition. Encouraging men to seek dermatological evaluation for genital concerns is vital, as dermatologists view all skin issues with the same professional lens.

In celebration of Men's Health Month, Hershel Dobkin, MD, FAAD, shed some light on a "taboo" topic.

Heather Raglin, Editor

Articles

Latest Updated Articles